IL2 and neuroblastoma: These findings were reported in a paper by Ladenstein et al. [21], in which authors concluded that dinutuximab beta and isotretinoin without subcutaneous IL-2 is to be considered the standard care for high-risk neuroblastoma patients after induction and HDT with SCT.